Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00752895 · ClinicalTrials.gov registry record · Phase 2
American Ginseng Extract in Preventing Respiratory Infection and in Reducing Antibiotic Use in Patients With CLL
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 293
- Enrollment target
NCT00752895: Completed Phase 2 study, sponsored by Wake Forest University Health Sciences.
NCT00752895 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 293 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (120% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00752895, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 293 participants
- Enrollment target
Study Summary
RATIONALE: American ginseng extract may prevent or reduce acute respiratory illness in patients with chronic lymphocytic leukemia. It is not yet known whether American ginseng extract is more effective than a placebo in preventing respiratory infections. PURPOSE: This randomized trial is studying the side effects of American ginseng extract and to see how well it works compared with a placebo in preventing respiratory infection and in reducing antibiotic use in patients with chronic lymphocytic leukemia.
Primary Outcome
An ARI day was defined as any day for which the subject experienced one or more respiratory symptoms (cough, sore throat, nasal or sinus congestion, or runny nose) and one or more systemic symptoms (feverishness, chills/sweats, myalgia (muscle aches), fatigue, headache, poor endurance or increased shortness of breath) between January and March.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT American ginseng
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 293 participants |
| Start Date | 2008-09-01 |
| Est. Completion | 2009-06-01 |
| Phase | Phase 2 |
What the finished NCT00752895 record still lists
NCT00752895 is an interventional study that assigns participants to a tested intervention. The registered 293 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (120% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00752895 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00752895 about?
NCT00752895 is a clinical study titled "American Ginseng Extract in Preventing Respiratory Infection and in Reducing Antibiotic Use in Patients With CLL". RATIONALE: American ginseng extract may prevent or reduce acute respiratory illness in patients with chronic lymphocytic leukemia. It is not yet known whether American ginseng extract is more effective than a placebo in preventing respiratory infections. PURPOSE: This randomized trial is studying t...
What is the current status of trial NCT00752895?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 293 participants. The study started on 2008-09-01. Estimated completion is 2009-06-01.
What interventions are being tested in trial NCT00752895?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), American ginseng (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00752895?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00752895's enrollment target sits among peer trials
293 191st of 2000 higher than 1,810 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05775159 · 294 participants · Phase 2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- NCT06262113 · 294 participants · NA
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
- NCT06338865 · 294 participants · NA
Short Title: Standard vs. Lower Pressure Pneumoperitoneum
- NCT06395467 · 294 participants · NA
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI